Comparative Pharmacology
Head-to-head clinical analysis: BARHEMSYS versus COMPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARHEMSYS versus COMPRO.
BARHEMSYS vs COMPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BARHEMSYS (amisulpride) is a selective dopamine D2/D3 receptor antagonist. It also has weak affinity for serotonin 5-HT2A and 5-HT2B receptors, with no significant activity at other dopamine or serotonin receptor subtypes. Its antiemetic effect is primarily mediated through blockade of D2 receptors in the chemoreceptor trigger zone (CTZ).
Prochlorperazine is a phenothiazine antipsychotic that primarily acts as a dopamine D2 receptor antagonist, with additional antagonism at D3, 5-HT2A, alpha1-adrenergic, and histamine H1 receptors. It also has antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
BARHEMSYS (amisulpride) 10 mg intravenously over 2 minutes, once daily for prevention of postoperative nausea and vomiting.
5 to 10 mg intramuscularly every 3 to 4 hours as needed; or 5 to 10 mg intravenously at a rate not exceeding 5 mg per minute; or 10 mg orally every 6 to 8 hours; maximum daily dose 40 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing in most patients.
Terminal elimination half-life: 4-6 hours in adults (prolonged in hepatic impairment, cirrhosis up to 10-12 hours; neonates up to 24 hours).
Renal excretion accounts for approximately 50% of the dose as unchanged drug; fecal elimination (including biliary) accounts for approximately 30-40%.
Renal: 70-80% as glucuronide and sulfate conjugates; biliary/fecal: <10% unchanged; <5% as unchanged drug in urine.
Category C
Category C
Antiemetic
Antiemetic